BACKGROUND AND PURPOSE:Gavestinel, GV150526, is a selective antagonist at the glycine site of the N-methyl-D-aspartate receptor. The safety and efficacy of GV150526 were studied in two phase III randomized placebo-controlled clinical trials of acute ischemic stroke patients within 6 h from onset [The Glycine Antagonist in Neuroprotection (GAIN) International and GAIN Americas Trials]. A planned MRI substudy within these trials investigated the effect of gavestinel on infarct volume. METHODS:Patients enrolled in the GAIN trials at designated MRI substudy sites were eligible if they had a pretreatment acute cortical lesion on diffusion-weighted MRI of at least 1.5 cm diameter or 5 cm(3). Final lesion assessment was performed on T(2)-weighted MRI at month 3. Blinded image analysis was performed centrally. The primary hypothesis was that gavestinel would attenuate lesion growth from baseline relative to placebo. RESULTS: A total of 106 patients were eligible, 75 (34 gavestinel, 41 placebo) of whom had month 3 scans (primary analysis population). No effects of gavestinel on infarct volume were observed in the primary or other analyses. However, significant associations of lesion volume to clinical severity and outcomes were observed. Ischemic lesion volume decrease was predictive of substantial clinical improvement. CONCLUSION: Consistent with the clinical outcomes in the GAIN trials, no effects of gavestinel on ischemic infarction was observed. Concordance of results of the clinical outcome trials with those of this infarct volume substudy as well the associations of infarct volume to clinical outcomes further support the potential role of infarct volume as a marker of outcome in dose finding and proof of principle acute stroke trials. Copyright (c) 2006 S. Karger AG, Basel.
RCT Entities:
BACKGROUND AND PURPOSE:Gavestinel, GV150526, is a selective antagonist at the glycine site of the N-methyl-D-aspartate receptor. The safety and efficacy of GV150526 were studied in two phase III randomized placebo-controlled clinical trials of acute ischemic strokepatients within 6 h from onset [The Glycine Antagonist in Neuroprotection (GAIN) International and GAIN Americas Trials]. A planned MRI substudy within these trials investigated the effect of gavestinel on infarct volume. METHODS:Patients enrolled in the GAIN trials at designated MRI substudy sites were eligible if they had a pretreatment acute cortical lesion on diffusion-weighted MRI of at least 1.5 cm diameter or 5 cm(3). Final lesion assessment was performed on T(2)-weighted MRI at month 3. Blinded image analysis was performed centrally. The primary hypothesis was that gavestinel would attenuate lesion growth from baseline relative to placebo. RESULTS: A total of 106 patients were eligible, 75 (34 gavestinel, 41 placebo) of whom had month 3 scans (primary analysis population). No effects of gavestinel on infarct volume were observed in the primary or other analyses. However, significant associations of lesion volume to clinical severity and outcomes were observed. Ischemic lesion volume decrease was predictive of substantial clinical improvement. CONCLUSION: Consistent with the clinical outcomes in the GAIN trials, no effects of gavestinel on ischemic infarction was observed. Concordance of results of the clinical outcome trials with those of this infarct volume substudy as well the associations of infarct volume to clinical outcomes further support the potential role of infarct volume as a marker of outcome in dose finding and proof of principle acute stroke trials. Copyright (c) 2006 S. Karger AG, Basel.
Authors: Antoni Dávalos; José Castillo; José Alvarez-Sabín; Julio J Secades; Joan Mercadal; Sonia López; Erik Cobo; Steven Warach; David Sherman; Wayne M Clark; Rafael Lozano Journal: Stroke Date: 2002-12 Impact factor: 7.914
Authors: Mark W Parsons; P Alan Barber; Jonathon Chalk; David G Darby; Stephen Rose; Patricia M Desmond; Richard P Gerraty; Brian M Tress; Peter M Wright; Geoffrey A Donnan; Stephen M Davis Journal: Ann Neurol Date: 2002-01 Impact factor: 10.422
Authors: Werner Hacke; Greg Albers; Yasir Al-Rawi; Julien Bogousslavsky; Antonio Davalos; Michael Eliasziw; Michael Fischer; Anthony Furlan; Markku Kaste; Kennedy R Lees; Mariola Soehngen; Steven Warach Journal: Stroke Date: 2004-11-29 Impact factor: 7.914
Authors: P Lyden; A Shuaib; K Ng; K Levin; R P Atkinson; A Rajput; L Wechsler; T Ashwood; L Claesson; T Odergren; E Salazar-Grueso Journal: Stroke Date: 2002-01 Impact factor: 7.914
Authors: Steven C Cramer; Camille Fitzpatrick; Michael Warren; Michael D Hill; David Brown; Laura Whitaker; Karla J Ryckborst; Lawrence Plon Journal: Stroke Date: 2010-03-04 Impact factor: 7.914
Authors: T Tourdias; P Renou; I Sibon; J Asselineau; L Bracoud; M Dumoulin; F Rouanet; J M Orgogozo; V Dousset Journal: AJNR Am J Neuroradiol Date: 2010-10-21 Impact factor: 3.825
Authors: Stephen J Phillips; Dingwei Dai; Arnold Mitnitski; Gordon J Gubitz; Karen C Johnston; Walter J Koroshetz; Karen L Furie; Sandra Black; Darell E Heiselman Journal: Stroke Date: 2007-08-23 Impact factor: 7.914
Authors: Jean-Marc Olivot; Michael Mlynash; Vincent N Thijs; Stephanie Kemp; Maarten G Lansberg; Lawrence Wechsler; Gottfried Schlaug; Roland Bammer; Michael P Marks; Gregory W Albers Journal: Stroke Date: 2008-06-19 Impact factor: 7.914
Authors: Martin R Gaudinski; Erica C Henning; Aaron Miracle; Marie Luby; Steven Warach; Lawrence L Latour Journal: Stroke Date: 2008-07-17 Impact factor: 7.914
Authors: José G Merino; Lawrence L Latour; Jason W Todd; Marie Luby; Peter D Schellinger; Dong-Wha Kang; Steven Warach Journal: Stroke Date: 2007-09-27 Impact factor: 7.914